New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:22 EDTRPTP, CORT, DRTX, EBS, EGLT, OVASJanney Capital to hold a conference
2nd Annual Healthcare 1x1 Corporate Access Day to be held in Boston on June 26.
News For RPTP;CORT;DRTX;EBS;EGLT;OVAS From The Last 14 Days
Check below for free stories on RPTP;CORT;DRTX;EBS;EGLT;OVAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
06:57 EDTEGLTEgalet management to meet with JMP Securities
Subscribe for More Information
September 18, 2014
08:31 EDTOVASOvaScience names Jeffrey Young as CFO
Subscribe for More Information
September 15, 2014
08:58 EDTRPTPRaptor Pharma should be owned ahead of potential catalysts, says JMP Securities
JMP Securities believes that Raptor has a number of potentially transformative upcoming catalysts. The firm thinks that adoption of the company's Proscybi drug could be a number of times higher than current levels, and it thinks that data due to be released over the next several months could be transformative for the company. The firm reiterates a $33 price target and Outperform rating.
September 11, 2014
09:38 EDTRPTPRaptor Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information
08:09 EDTEGLTEgalet issued U.S. patents covering product candidates
Egalet announced the issuance of patents by the U.S. Patent and Trademark Office covering Egalet's product candidates and the company's proprietary Guardian Technology.
September 8, 2014
13:53 EDTEBSEmergent BioSolutions awarded contract valued at up to $29M with NIAID
Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a dry formulation of NuThrax, also known as AV7909, the company’s next generation anthrax vaccine candidate. This five-year contract, valued at up to $29M, provides funding for manufacturing and non-clinical activities through the preparation of an Investigational New Drug application to the U.S. Food and Drug Administration. The dry formulation of NuThrax is intended to increase stability of the vaccine candidate at ambient and higher temperatures, with the objective of eliminating the need for cold chain during shipping and storage. NuThrax is comprised of BioThrax in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909. The company is currently conducting a randomized, parallel-group, active-controlled, double-blind Phase 2 study designed to evaluate the safety and immunogenicity of NuThrax for post-exposure prophylaxis of anthrax infection using two- and three-dose immunization schedules and two dose levels. This development contract HHSN272201400038C will be administered through NIAID, part of the National Institutes of Health of the U.S. Department of Health and Human Services.
10:51 EDTEBSEmergent BioSolutions receives $29M HHS contract
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use